NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a efficiency magnificence firm with a concentrate on constructing an aesthetic portfolio of shopper manufacturers, at present reported the grant of an mixture of 10,845 restricted inventory models (RSUs) of the corporate’s frequent inventory to five newly employed non-executive workers of the corporate. The awards have been permitted by the compensation committee of the corporate’s board of administrators underneath the Evolus (NASDAQ:)’ 2023 Inducement Incentive Plan, with a grant date of September 12, 2024, and a vesting graduation date of September 7, 2024, as an inducement materials to the brand new workers coming into into employment with Evolus in accordance with Nasdaq Itemizing Rule 5635(c)(4).
The RSUs vest 25% on every annual anniversary of the vesting graduation date. The awards are topic to the phrases and situations of the 2023 Inducement Incentive Plan and the phrases and situations of RSU settlement protecting the grant, together with necessities to stay constantly employed on every vesting date.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a world efficiency magnificence firm evolving the aesthetic neurotoxin marketplace for the subsequent technology of magnificence shoppers by way of its distinctive, customer-centric enterprise mannequin and revolutionary digital platform. Our mission is to turn into a world, multi-product aesthetics firm primarily based on our flagship product, Jeuveau ® (prabotulinumtoxinA-xvfs), the primary and solely neurotoxin devoted solely to aesthetics and manufactured in a state-of-the-art facility utilizing Hello-Pure™ know-how. Evolus is increasing its product portfolio having entered right into a definitive settlement to be the unique U.S. distributor of Evolysse™, and the unique distributor in Europe of Estyme ®, a line of distinctive dermal fillers presently in late-stage growth.
Go to us at www.evolus.com, and observe us on LinkedIn, X, Instagram or Fb (NASDAQ:).
Jeuveau ® and Nuceiva ®, are registered logos and Evolysse™ is a trademark of Evolus, Inc.
Hello-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme ® is a trademark of Symatese Aesthetics S.A.S.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240927335094/en/
Evolus Contacts:
Traders:
Nareg Sagherian
Vice President, Head of World Investor Relations and Company Communications
Tel: 248-202-9267
E mail: ir@evolus.com
Media:
E mail: media@evolus.com
Supply: Evolus
